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The role of preformed xenoreactive antibodies in 
xenograft r ecipients is u nknown. Humans and ba-
boons possess red cell agglutinating activity associ-
ated with isohemagglutinins and heteroagglutinins 
(HA). We examined the role of HA in two patients who 
received ABO-identical baboon livers. Human antiba-
boon HA were assessed by correlating serial titers 
with studies for r ej ection. Serial direct antiglobulin 
testing (DAT) was used t o detect bab oon a n tih uman 
HA, potentially produ ced b y transplanted p assenger 
lymphocytes. Patient 1 su rvived 70 days. The hum n 
anti baboon HA titers remained essentially uncha n ged 
from preoperative values. Although hyperacute rejec-
tion did not occur, and there was only mild cellular 
rejection, liver function was suboptimal. Postreperfu-
sion immunoglobulin and complement deposition a n d 
histologic changes suggested complement-mediated 
injury. DAT testing was negative except for passively 
acquired anti-A from t r a nsfusion. At autopsy there 
was marked bile stasis, b ut no rejection. Patient 2 
survived 26 days with essent ially unchanged HA titers 
until preterminal. Although there was no hyperacute 
rejection and only mild humoral rejection (without 
cellular rejection), suboptimal liver function and bile 
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stasis were again n oted. Postreperfusion immunoglob-
ulin and complement deposition again suggested com-
plemen t -mediated injury. DAT testing was negative. 
At autopsy there was no r ejection. Human antibaboon 
HA do not a ppear to be assoc iated with hyperacute or 
cellular rejection, b ut t h eir role in the complement-
mediated injury, suspected in both cases, cannot be 
definit ively excluded. Baboon antihuman HA were not 
detected in either patient. 
The rela tionship between xenoreactive antibodies and xe-
nograft rejection remains unclear. Candidate antibodies in-
clude those which cause hemagglutination or lymphocytotox-
icity (1). ABH antibodies have been associated with early loss 
of human hepatic allografts (2, 3) and baboon renal (4) and 
cardiac (5) xenografts. Baboons do not express ABH antigens 
on their red cells (6, 7) but these antigens have been demon-
strated on baboon vascular endothelium (8). Non-ABH anti-
bodies capable of agglutinating red cells from other species 
(heteroagglutinins) are p resent in both humans and baboons 
(9) and have been implicated in renal xenograft rejection (4 ). 
Passenger lymphocytes transplanted with the baboon liver 
represent a potential source of baboon antihuman heteroag-
glutinin (HAY that could cause hemolysis or a positive direct 
antiglobulin test (DAT). Conversely, human sera contain an-
tibaboon HA that could crossreact with baboon hepatocytes 
or endothelial cells causing rejection. 
We report the results of red cell serologic studies to detect 
HA and their clinical correlation in two patients who under-
went hepatic xenotransplantation using ABO-identical ba-
boon donors. 
'" Abbreviations: DAT, direct anti globulin test; HA, heteroaggluti-
nin. 
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MATERIALS AND METHODS 
Patients. The case histOlies for these patients have been de-
scribed in detail elsewhere (10, 11). Briefly, Patient 1 was a 35-year-
old man with end-stage liver disease due to hepatitis B virus. The 
patient was also HIV I- positive without evidence of immune defi-
ciency. The patient's blood group was A-positive and he received a 
liver from a group A baboon. The red cell antibody screen was 
negative but the patient did have lymphocytotoxic antibodies against 
baboon donor lymphocytes (positive lymphocytotoxic crossmatch). 
Patient 2 was a 62-year-old man with end-stage liver disease due to 
hepatitis B. The patient's blood group was B-positive and he received a 
liver from a group B baboon. His red cell antibody screen was negative 
but the patient did have lymphocytotoxic antibodies against baboon 
donor lymphocytes (positive lymphocytotoxic crossmatch). 
Patient testing. Serum and EDTA samples were obtained on both 
patients preoperatively and daily postoperatively for at least 3 weeks 
and then weekly. The serum titers of human antibaboon HA were 
determined on each sample. A DAT using antihuman IgG and anti-
human C3 (Ortho Diagnostics, Raritan NJ) was performed weekly. 
Immune hemolysis was defined as a decrease in hemoglobin with a 
rise in indirect bilirubin and a positive DAT. 
Determination of anti baboon HA titers. Patient serum was seri-
ally diluted nd incubated \vith a 3-5% suspension of washed red 
cells from the baboon donor at room temperature and antiglobulin 
(Coomb's) phase. Titers were repeated on patient serum treated with 
dithiothreitol to inactivate IgM antibody. Each of these samples was 
tested in parallel with a preoperative serum sample. The last tube 
showing macroscopic or microscopic reactivity was considered the 
endpoint. 
ABO determination of baboons. Preparation of baboon serum: 
Complement was inactivated by heat-treating baboon serum at 56°C 
for 60 min. Heated baboon serum was then adsorbed with washed 
human group 0 red blood cells at 4°C for 2 to 18 hr to remove baboon 
antihuman HA. Reverse typing: Adsorbed baboon serum was tested 
against washed human AI, B, and 0 cells using 2 drops of serum per 
drop of cells. 0 cells were used as a control to monitor the removal of 
antihuman HA. 
RESULTS 
Patient 1: clinical course. The patient was treated with an 
immunosuppressive regimen that included FK506, steroids, 
prostaglandins, and cyclophosphamide. Surgery was toler-
ated well and the patient was eating and walking within 5 
days. A transient increase in plasma hemoglobin was noted 
on day 2 without evidence of immune hemolysis. There was 
no other clinical or laboratory evidence of hemolysis until late 
in the course (day 65) when the patient developed sepsis 
complicated by disseminated intravascular coagulation. 
Intraoperative liver biopsy after reperfusion revealed si-
nusoidal neutrophilia with 3+ IgG and 3+ IgM sinusoidal 
deposition and focal C3 deposits (Figs. 1 and 2). Subsequent 
biopsies showed only mild evidence of cellular rejection and 
decreasing immunoglobulin and complement deposition with 
virtual disappearance by day 24 (Figs. 3 and 4). By day 55, 
minimal sinusoidal deposition of IgG and IgM (no C3) was 
again present, which increased in the final biopsy (Table 1). 
Despite the lack of histologic evidence of rejection, subopti-
mal xenograft function was observed. Biliary canalicular en-
zymes were m arkedly elevated and serum albumin levels 
were persistently less than 2 g/dl. The patient died on day 70 
of a subarachnoid hemorrhage due to invasive aspergillosis. 
At autopsy there was no evidence of cellular rejection, but the 
entire biliary tree was filled with inspissated bile. 
'.-
-. I • ~ .. _~oK ,- , - t ,-- .,f-t  o .. ...... ,. .. 
,.' .. . 
" . ' .. ' \ , 
1~ .. ,.( 0", ~ 
e'. '; • • ~ ~K" . .  .. 
. !I ~ .. -,. ..... 
... 
• .. • 1.. \ . 
. ' 
.. 'r " ~KF ~K 
oet"' 
, , 
'. " .... .. fII" ~ 
'f • .. ~ ry~fD~ . .. . ~I . __ t.£- oO • ...,. 
FIGURE 1. Postreperfusion liver biopsy in patient 1 showing 3+ si-
nusoidal staining of IgG (20 x). 
FIGURE 2. Postreperfusion liver biopsy in patien t 1 showing 3 si-
nusoidal staining ofIgM (20 X). 
FIGURE 3. Day 24 liver biopsy in patien t 1 showing weak sinusoidal 
staining of IgG (20 X). 
Patient 1: serologic data (Table 1). The human antibaboon 
HA titers in both neat and di thioth reitol (DTI)-treated se-
rum remained essentially unchanged from preoperative val-
ues. Titers with dithiothreitol- tr 0 a ted sera were consistently 
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Date 
Preop. 
lntraopb 
POD 3" 
POD 7 
POD 12 
POD 14 
POD 24 
POD 35 
POD 55 
POD 61 
POD 65 
POD 69 
POD 70 
a Sinus idal staining. 
b Postreperfusion. 
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TABLE 1. Patient 1 HA titers and hepatic immunoglobulin deposition 
Patient sera vs. baboon RBC IYIT-treated sera vs. baboon RBC 
RT AGT RT AGT 
1:4 1:32 1:1 1:2 
1:2 1:64 
Neg 1:128 Neg Neg 
eg 1:64 
eg 1:64 Neg Neg 
Neg 1:64 Neg Neg 
Neg 1:32 Neg Neg 
' eg 1:16 Neg Neg 
Neg 1:32 eg Neg 
1:4 1:1 
Patient died 
C POD, postoperative day; DTI, dithiothreitol; RT, room temperature; AGT, antiglobulin phase. 
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FIGURE 4. Day 24 liver biopsy in patient 1 showing disappear nee of 
sinusoidal IgM staining (20 x). FIGURE 5. Postreperfusion liver biopsy in patient 2 showing 3+ si-
nusoidal staining of IgG (20 x ). 
negative postoperatively, indicating that the antibody was 
predominantly IgM. The DAT was t ransiently positive on 
days 7-18 due to anti-A passively acquired from a group. 0 
platelet transfusion. The patient's red cell antibody screen 
remained negative th roughout hospitalization. 
Patient 2: clinical course. The patient was treated with an 
immunosuppressive regimen that included FK506, steroids, 
prostaglandins, and cyclophosphamide. Surgery was compli-
cated by acute renal failure an d the patient remained icteric 
and comatose postoperatively. A transient increase in plasma 
hemoglobin was noted on day 4 and 9 without evidence of 
immune hemolysis . 
As in patient 1, the intr aoperative liver biopsy after reper-
fusion revealed sinusoidal neutrophilia with 3 I- IgG and 3+ 
IgM sinusoidal and focal complement deposition (Figs. 5 and 
6), but no hepatocellular necrosis or vascular thrombosis 
suggesting hyperacute rejection. Subsequent liver biopsies 
on days 4, 8, and 12 showed a marked decrease in sinusoidal 
IgM staining but persistent JgG staining suggestive of mild 
humoral rejection (Table 2, Figs. 7 and 8). There was no 
evidence of cellular r ejection. Although there was only mild 
humoral rejection, suboptimal graft func tion was manifested 
by increasingly severe bile stasis histologically and persis-
FIGURE 6. Postreperfusion liver biopsy in patient 2 showing 3+ si-
nusoidal staining oflgM (20X). 
tent hypoalb uminemia (2 g/dl). During the third postopera-
tive w ek, sepsis and peritonitis developed a a result of an 
intestinal anastomotic I ak. Despite repair of the leak and 
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TABLE 2. Patient 2 HA titers and hepatic immunoglobulin deposition 
Date 
-----
Preop. 
In traop . b 
POD 3" 
POD 4 
POD 8 
POD 12 
POD ] 5 
POD 22 
POD 23 
POD 24 
POD 25 
POD 26 
a Sinusoidal sta ining. 
b Postreperfusion. 
Curren L pt Sera vs. baboon MC 
---
RT AGT 
1:4 1:32 
eg 1:16 
Neg 1:64 
Neg 1:64 
eg 1:32 
1:32 1:256 
1:64 1:512 
1:16 1:256 
1:82 1:1024 
Patient died 
DTT-treated sera vs. baboon RBC Liver biopsy- Ig staining" 
RT AGT [gG IgM 
1:4 1:16 
+ + + +++ 
+++ +/-
Neg 1:1 ++ +/-
+ + + +/ -
Neg 1:1 
1:1 1:256 
1:2 1:64 
C POD, postoperative day; DT'I', dithiothreitol; RT, room temperature; AGT, antiglobulin phase. 
FIG RE 7. Day 4 liver biopsy in patient 1 showing persistant 3+ 
sinusoidal staining ofIgG (20 x). 
FIGURE 8. Day 4 liver biopsy in patient 2 showing marked decrease 
in sinusoidal Tg staining (20 x ). 
antibiotic therapy the patient died on day 26. Postmortem 
examination of the liver showed diffuse necrosis with vascu-
lar thrombosis but no evidence of cellul l' rejection. 
Patient 2: serologic data (Table 2). The human antibaboon 
HA titer was predominantly IgM and remained at or near 
preoperative levels until the terminal phase of life when it 
rose to a titer of 1:1024 at the antiglobulin phase. Both neat 
and DTT-treated sera showed a similar rise in titer, suggest-
ing that IgG antibaboon HA levels were also increased. The 
DAT and the patient's red cell antibody screen remained 
negative throughout hospitalization. 
DISCUSSION 
Preformed naturally occurring antibodies in xenograft re-
cipients have been postulated to account for hyperacute re-
jection seen in some, but not all, species combinations (1). 
Hyperacute rejection appears to be the most severe manifes-
tation of a spectrum of "humoral" complement activation 
syndromes that may be antibody mediated (classical path-
way) or non-antibody mediated (alternate pathway) (11). A 
"slow-motion" version of this humoral process has been de-
scribed in allografts and appears to be characteristic of con-
cordant xenograft transplants (12). Previously reported ba-
boon-to-human renal transplant recipients experienced early 
graft loss but not hyperacute rejection despite the presence of 
HA and isohemagglutinins (4). Similarly, hyperacute rejec-
tion was not observed in the only baboon-to-human cardiac 
transplant recipient despite the presence of both preformed 
isohemagglutinins and lL'\ (5). 
The potential clinical significance of human antibaboon 
HA was assessed by following the titer and correlating the 
results with liver biopsy studies for rejection. The signifi-
cance of ABH isohemagglutinins was not evaluable in our 
two patients because ABO-identical baboon donors were se-
lected. HA directed at baboon red cells were detected preop-
eratively in both patients. There was little change in HA 
titers in either patient except for a preterminal rise in pa-
tient 2. Liver biopsy immunofluorescent staining showed 
prominent sinusoidal deposition ofimmunoglobu Hn and com-
plement immediately after reperfusion of the xenograft in 
both patients. In patient 1 sinusoidal IgG and IgM deposition 
markedly decreased in subsequent biopsies and then reap-
peared late in the hospital course. In patient 2 IgM deposi-
tion markedly decreased but IgG persisted. The lack of cor-
relation between HA titers and observed changes in 
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sinusoidal staining for IgG and IgM could be due to binding 
of only the highest-affinity HA antibodies to the graft or to 
binding of non-HA antibodies such as lymphocytotoxic or 
endothelial antibodies . The disappearance of lymphocytoxic 
antibodies, which were present in both patients prior to 
transplant, may be due to adsorption of these antibodies to 
the graft. 
Despite the early deposition of immunoglobulin and com-
plement in the grafts, histologic evidence of hyperacute re-
jection was not present. These findings support the observa-
tions in baboon renal transplantation that HA do not mediate 
hyperacute rejection. However, suboptimal graft function 
must still be explained. Both patients demonstrated histolog-
ical and serological evidence for complement activation in-
jury (11). This injury may represent a manifestation of a 
"slow-motion" humoral rejection as described above (12). An-
tibody-dependent complement activation via a subset of HA 
antibodies or via non-HA antibodies (i.e., lymphocytotoxic, 
endothelial cell) cannot be completely excluded. The hemag-
glutination technique used in this study is limited in that it 
reflects only gross changes in HA and does not detect anti-
bodies with specificities not expressed on red cells. It is also 
possible that the complement injury was mediated through 
alternate pathway activation (antibody-independent path-
way). 
Passenger lymphocytes transplanted with human hepatic 
grafts can produce both ABH and non-ABH red cell-directed 
antibodies capable of causing hemolysis (13, 14). Passenger 
lymphocytes transplanted with the baboon liver are a poten-
tial source of baboon antihuman HA since both baboon do-
nors as well as all 11 other baboons tested (data not shown), 
possess HA directed against human red cells. Production of 
these antibodies was assessed by following the results of 
serial direct antiglobulin testing and clinical or laboratory 
evidence of hemolysis. The lack of a positive DAT (except for 
a transient passively acquired anti-A) in either patient sug-
gests that either these antibodies were not produced or were 
produced in undetectable amounts. The fate of the trans-
planted baboon lymphocytes capable of producing the HA is 
unknown. ABH antibodies produced by passenger lympho-
cytes from ABO-unmatched human hepatic allografts are 
detected in 40-60% of cases and are typically transient, only 
persisting for several weeks (13, 14). The transient early 
hemolysis observed in both patients did not appear to have 
an immune etiology and remains unexplained. The late he-
molysis in patient 2 was thought to be associated with a 
consumptive coagulopathy. 
In summary, human antibaboon HA do not appear to be 
associated with hyperacute rejection or cellular rejection, but 
their role in the complement-mediated injury, suspected in 
both cases, cannot be definitively excluded. Baboon antihu-
man HA were not detected in either patient. The presence of 
HA and/or hemolysis should be assessed in future xenograft 
recipients to evaluate their potential clinical significance. 
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